Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Signet Ring Cell | 1 | 2021 | 81 | 0.740 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 710 | 0.590 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 480 | 0.570 |
Why?
|
| Germ-Line Mutation | 3 | 2022 | 1887 | 0.550 |
Why?
|
| Cadherins | 1 | 2021 | 906 | 0.550 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 2063 | 0.390 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 1483 | 0.370 |
Why?
|
| Antigens, CD | 1 | 2021 | 4032 | 0.370 |
Why?
|
| Mutation | 4 | 2022 | 30266 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5434 | 0.260 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2022 | 3200 | 0.260 |
Why?
|
| Immunotherapy | 1 | 2021 | 4756 | 0.240 |
Why?
|
| Neoplasms | 2 | 2021 | 22389 | 0.200 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 6982 | 0.190 |
Why?
|
| Kidney Neoplasms | 4 | 2022 | 4300 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 13594 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 2251 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 13698 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 318 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 1769 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 1091 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 808 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 799 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 21188 | 0.110 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2022 | 1077 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 2433 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 4785 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 59739 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 4528 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3671 | 0.080 |
Why?
|
| Prevalence | 2 | 2022 | 15879 | 0.070 |
Why?
|
| Aged | 6 | 2021 | 171786 | 0.070 |
Why?
|
| Middle Aged | 6 | 2021 | 223737 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2022 | 18068 | 0.060 |
Why?
|
| Smoking | 1 | 2022 | 9094 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8664 | 0.060 |
Why?
|
| Adult | 5 | 2021 | 223851 | 0.060 |
Why?
|
| Humans | 14 | 2022 | 768970 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5716 | 0.060 |
Why?
|
| Genealogy and Heraldry | 1 | 2021 | 29 | 0.050 |
Why?
|
| Male | 8 | 2022 | 365203 | 0.050 |
Why?
|
| Benzoxazoles | 1 | 2022 | 92 | 0.050 |
Why?
|
| Validation Studies as Topic | 1 | 2021 | 162 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 139 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11886 | 0.040 |
Why?
|
| Platinum | 1 | 2021 | 222 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 54962 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 11230 | 0.040 |
Why?
|
| Penetrance | 1 | 2021 | 386 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2021 | 371 | 0.040 |
Why?
|
| Pyrimidines | 2 | 2022 | 3048 | 0.040 |
Why?
|
| Female | 6 | 2021 | 397515 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 60131 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 644 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 736 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 1762 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 1528 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 878 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 2126 | 0.030 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 496 | 0.030 |
Why?
|
| Immunity | 1 | 2022 | 1003 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1514 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2021 | 65480 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2022 | 1904 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2022 | 4148 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3621 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 2748 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2022 | 2029 | 0.020 |
Why?
|
| Piperazines | 1 | 2021 | 2553 | 0.020 |
Why?
|
| Pyridines | 1 | 2021 | 2895 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3952 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12873 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10486 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 17173 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 9264 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2022 | 81903 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18354 | 0.010 |
Why?
|
| Prognosis | 1 | 2021 | 30046 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39394 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23653 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 42683 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 82072 | 0.010 |
Why?
|
| Child | 1 | 2021 | 80960 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 89244 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 169335 | 0.010 |
Why?
|
Concepts
(85)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(34)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_